Krystal Biotech Inc (KRYS)

Pretax margin

		Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Earnings before tax but after interest (EBT) (ttm)	US$ in thousands	59,126	12,897	-29,812	-140,409	-135,307	-139,975	-129,729	-115,468	-103,723	-69,570	-58,147	-52,168	-42,638	-32,167	-27,141	-21,803	-20,318	-19,088	-16,486	-14,490
Revenue (ttm)	US$ in thousands	102,227	56,573	9,365	809	809	0	0	0	0	0	0	0	0	0	0	0	542	1,125	1,342	1,515
Pretax margin		57.84%	22.80%	-318.33%	-17,355.87%	-16,725.22%	—	—	—	—	—	—	—	—	—	—	—	-3,748.71%	-1,696.71%	-1,228.46%	-956.44%

March 31, 2024 calculation

Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $59,126K ÷ $102,227K
= 57.84%

The pretax margin of Krystal Biotech Inc has shown significant fluctuations over the periods presented. The pretax margin was exceptionally high at 57.84% in March 2024, indicating a strong profitability before accounting for taxes. In December 2023, the pretax margin decreased to 22.80%, still reflecting a healthy level of profitability.

However, the pretax margin turned negative in the subsequent quarters, reaching extreme values such as -318.33% in September 2023 and -17,355.87% in June 2023. These negative figures suggest that the company incurred significant losses before taxes during these periods.

It is important to further investigate the reasons behind the negative pretax margins to identify any underlying issues affecting Krystal Biotech's profitability. Additional data and analysis would be necessary to understand the factors driving these fluctuations and to assess the company's overall financial performance and sustainability.